BMC Public Health
Department of Public Health and Primary Care, Primary Care Unit, University of Cambridge, Cambridge, CB2 0SR, UK.
Published: February 2025
Background: Recent advances mean that innovations are emerging that enable better stratification of individuals based on their risk of cancer so that screening or diagnostic investigations can be targeted to those at greatest need. We explored the views of the public, from a societal perspective, of using such risk-based innovations to identify people's cancer risk and allocating healthcare accordingly.
Methods: We conducted three community juries, each with 7-9 participants. Participants were informed about the topic and potential novel risk-based innovations through a series of presentations from experts and discussions. Polygenic risk scores, geodemographic segmentation, continuous monitoring of biomarkers, minimally invasive tests, artificial intelligence analysis of medical records, and wearable devices were used as examples. The participants then deliberated over the research questions before reporting their verdicts on the acceptability of these novel data-based approaches in principle. Transcripts were analysed using codebook thematic analysis.
Results: All juries found that the proposed risk-based approaches to cancer healthcare were, in general, acceptable. Primarily this was because the approaches would enable use of information in a positive and constructive way. However, there were a number of qualifiers or caveats. In particular, participants highlighted the necessity of using accurate and robust data with a well-evidenced association with cancer risk. They also expressed concerns about unintended consequences such as for insurance, scams or erosion of personal liberty, and the burden to participate in data collection across society. All agreed that opting-out must be straightforward.
Conclusions: Informed members of the public supported the concept of using innovations to estimate cancer risk and inform healthcare. Their priorities for accuracy, data security, participation burden, and personal liberty and choice tended to overlap with those of developers and policymakers. Work to ready these innovations for implementation should continue, with the public's priorities accounted for in their development and dissemination in order to address any unintended consequences upfront.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869612 | PMC |
http://dx.doi.org/10.1186/s12889-025-21996-x | DOI Listing |
Ann Intern Med
March 2025
Charité Universitätsmedizin Berlin, Berlin, Germany (E.S.).
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) organization updated its existing clinical practice guideline in 2024 to provide guidance on the evaluation, management, and treatment of chronic kidney disease (CKD) in adults and children who are not receiving kidney replacement therapy.
Methods: The KDIGO CKD Guideline Work Group defined the scope of the guideline and determined topics for systematic review. An independent Evidence Review Team systematically reviewed the evidence and graded the certainty of evidence for each of the review topics.
BMC Public Health
February 2025
Department of Public Health and Primary Care, Primary Care Unit, University of Cambridge, Cambridge, CB2 0SR, UK.
Background: Recent advances mean that innovations are emerging that enable better stratification of individuals based on their risk of cancer so that screening or diagnostic investigations can be targeted to those at greatest need. We explored the views of the public, from a societal perspective, of using such risk-based innovations to identify people's cancer risk and allocating healthcare accordingly.
Methods: We conducted three community juries, each with 7-9 participants.
AAPS J
February 2025
Drug Product Development, Medicine Development and Supply, GSK, Ware R&D, Hertfordshire, UK.
The IQ Consortium Uniformity Testing Working Group reviewed the current BU and CU testing practices among ten member companies. All ten companies presented their current approach to BU and CU testing at the three stages of Product Lifecycle Management: the Process Design Stage, the Process Qualification Stage, and the Continuous Verification Stage. With this information on hand, the Uniformity Testing Working Group members developed a risk-based approach to BU and CU testing, and proposed innovative methods to reduce or eliminate blend sampling based on risk to Uniformity of Dosage Unit (UDU) testing.
View Article and Find Full Text PDFTher Innov Regul Sci
February 2025
Takeda Pharmaceuticals, Cambridge, MA, USA.
The traditional clinical trial monitoring process, which relies heavily on site visits and manual review of accumulative patient data reported through Electronic Data Capture system, is time-consuming and resource-intensive. The recently emerged risk-based monitoring (RBM) and quality tolerance limit (QTL) framework offers a more efficient alternative solution to traditional SDV (source data verification) based quality assurance. These frameworks aim at proactively identifying systematic issues that impact patient safety and data integrity.
View Article and Find Full Text PDFPrev Vet Med
May 2025
Livestock Innovation, SEGES Innovation P/S, Agro Food Park 15, Aarhus N 8200, Denmark. Electronic address:
In May 2022, a national control program targeting porcine reproductive and respiratory syndrome virus was launched in Denmark, and the first regions are approaching a PRRS-free status. Hence, the question now arises as to how the surveillance should be performed to identify new incursions of the PRRS virus in PRRS-free regions as early as possible. The aim of the present study was to quantify the early detection sensitivity of the current and alternative PRRS surveillance systems in Denmark at a regional level.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.